Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
5 evidence topics · 3 sources
Summary
Available procedural treatments can be limited by complications, recurrence, and repeated procedures. The Japanese guideline recommendation addressing skin and mucosal lymphatic malformations has a strength rating of 2, described as weak, and an evidence rating of D, described as very weak.
A systematic review of sirolimus reported improvement in 46 of 50 evaluable individuals (92%), mostly previously treated, while identifying the need for prospective controlled trials. These heterogeneous supporting data do not establish the comparative effectiveness of QTORIN rapamycin against individual procedures, compounded topical formulations, or systemic therapy.